TMO EPM

TMO EPM

TMO EPM

Transplante de Medula Óssea - Unifesp - EPM - Hospital São Paulo

33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
  • 21 күн бұрын

33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

32 - The addition of bortezomib to rituximab, cytarabine and dexa in R/R mantle cell lymphoma
  • 21 күн бұрын

32 - The addition of bortezomib to rituximab, cytarabine and dexa in R/R mantle cell lymphoma

31 - Remission induction vs immediate allo HSCT for relapsed or poor responsive AML (ASAP)
  • 28 күн бұрын

31 - Remission induction vs immediate allo HSCT for relapsed or poor responsive AML (ASAP)

30 - Ibrutinib + immunochemo +/- ASCT vs immunochemo + ASCT in mantle cell lymphoma (TRIANGLE)
  • Ай бұрын

30 - Ibrutinib + immunochemo +/- ASCT vs immunochemo + ASCT in mantle cell lymphoma (TRIANGLE)

Aula da Disciplina de Hematologia e Hemoterapia
  • Ай бұрын

Aula da Disciplina de Hematologia e Hemoterapia

Aula da Disciplina de Hematologia e Hemoterapia da UNIFESP 17/06/24
  • Ай бұрын

Aula da Disciplina de Hematologia e Hemoterapia da UNIFESP 17/06/24

Aulas da Disciplina de Hematologia e Hemoterapia da UNIFESP 10/06/24
  • Ай бұрын

Aulas da Disciplina de Hematologia e Hemoterapia da UNIFESP 10/06/24

Cuidados paliativos em Hematologia
  • Ай бұрын

Cuidados paliativos em Hematologia

Reações Transfusionais Hemolíticas
  • Ай бұрын

Reações Transfusionais Hemolíticas

Aula de LLC - Prof Matheus Vescovi Gonçalves
  • 2 ай бұрын

Aula de LLC - Prof Matheus Vescovi Gonçalves

Aula de Hemoterapia - AHAI
  • 2 ай бұрын

Aula de Hemoterapia - AHAI

29 - Younger unrelated donors may be preferable over HLA match in the PTCy era
  • 2 ай бұрын

29 - Younger unrelated donors may be preferable over HLA match in the PTCy era

Ciclofosfamida pós-transplante como profilaxia de DECH
  • 2 ай бұрын

Ciclofosfamida pós-transplante como profilaxia de DECH

Mobilização de células progenitoras hematopoéticas
  • 2 ай бұрын

Mobilização de células progenitoras hematopoéticas

28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia
  • 3 ай бұрын

28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia

27 - Outcomes of allogeneic HSCT for relapsed or refractory diffuse large B-cell lymphoma
  • 3 ай бұрын

27 - Outcomes of allogeneic HSCT for relapsed or refractory diffuse large B-cell lymphoma

26 - Gilteritinib as Post-Transplant Maintenance for AML With Mutation of FLT3
  • 3 ай бұрын

26 - Gilteritinib as Post-Transplant Maintenance for AML With Mutation of FLT3

25 - PTCy vs ATG - RIC alloSCT - matched sibling or 10/10 HLA matched unrelated donors
  • 4 ай бұрын

25 - PTCy vs ATG - RIC alloSCT - matched sibling or 10/10 HLA matched unrelated donors

24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with AML
  • 4 ай бұрын

24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with AML

23 - DPD vs PD in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up
  • 4 ай бұрын

23 - DPD vs PD in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up

22 - Tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention
  • 5 ай бұрын

22 - Tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention

21 - Outcomes of patients with large B-cell lymphoma treated with axi-cel and prophylactic steroids
  • 5 ай бұрын

21 - Outcomes of patients with large B-cell lymphoma treated with axi-cel and prophylactic steroids

20 - Azacitidine, Venetoclax, and Gilteritinib in FLT3-Mutated AML
  • 5 ай бұрын

20 - Azacitidine, Venetoclax, and Gilteritinib in FLT3-Mutated AML

19 - Zanubrutinib Versus Ibrutinib in Waldenstrom Macroglobulinemia: Final Analysis - ASPEN Study
  • 6 ай бұрын

19 - Zanubrutinib Versus Ibrutinib in Waldenstrom Macroglobulinemia: Final Analysis - ASPEN Study

18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
  • 6 ай бұрын

18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
  • 6 ай бұрын

17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Linfoma Primário de Mediastino
  • 7 ай бұрын

Linfoma Primário de Mediastino

16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML
  • 7 ай бұрын

16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML

LGL e clone T de significado incerto
  • 8 ай бұрын

LGL e clone T de significado incerto

Пікірлер